OA 09.06 – A Phase Ib trial of savolitinib plus gefitinib for Chinese patients with EGFR-mutant MET-amplified advanced NSCLC (WCLC 2017)

Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Handzel, M.M. Frigault, G. Ahmed, C. Egile, S. Morgan, Yi-Long Wu

 HMPL-504_Ph1b2_NSCLC_Iressa_Combo_WCLC_2017_thumb
 

Venue: IASLC 18th World Conference on Lung Cancer in Yokohama, Japan
Session: OA 09 – EGFR TKI Resistance (ID 663)
Presenter: Jin-Ji Yang
Date: Tuesday, October 17, 2017

 

For a summary of the data presented, please see the Chi-Med company overview presentation.